TERN

Terns Pharmaceuticals, Inc. TERN

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-23.57M

Quarter to Dec 31

Free cash flow

$-19.08M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$659.7K total
MIZUHO SECURITIES USA LLC
$584.3K0.0%
IFP Advisors, Inc
$75.4K0.0%
See all 2 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q4 2025
EDGAR

ROIC

Q4 2025
EDGAR

Free Cash Flow

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/TERN

Earnings Per Share

13fpro.ai/company/TERN

Loading ratio trend…

TERN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Terns Pharmaceuticals, Inc. (TERN): stock profile, AI score and financials

Terns Pharmaceuticals, Inc. (TERN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. TERN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2025), Terns Pharmaceuticals, Inc. reports net income of $-23.6M, free cash flow of $-19.1M. TERN trades on the Nasdaq exchange and files with the SEC under CIK 1831363. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TERN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Terns Pharmaceuticals, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1831363 →